May, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Kaltman frames the talk around persistent disparities in cancer screening, citing data from major reports like the AACR Cancer Disparities Progress Report and the President’s Cancer Panel. Examples include the underutilization of advanced breast imaging among Black women and lower cervical cancer screening rates among LGBTQ+ individuals. These disparities are attributed to multifactorial barriers, including limited access, systemic bias, and inadequacies in current screening guidelines.
May, 2025 | Grand Rounds in Hematology & Oncology, Leukemia, Webinars
Dr. Iacobucci focuses on elucidating the genomic landscape of these malignancies through bulk and single-cell sequencing, identifying genetic drivers, and developing functional models to explore targeted therapies. She highlights the importance of molecular characterization for subclassifying leukemias and informing treatment strategies.
April, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Dengel provides an overview of the integration of immunotherapy with surgical oncology, focusing on strategies to modulate the tumor microenvironment to enhance immune response in solid tumors.
April, 2025 | Cancer Therapy-Related Cardiac Dysfunction (CTRCD), Grand Rounds in Hematology & Oncology, Webinars
Dr. Abbate defines CTRCD as a decrease in left ventricular ejection fraction (LVEF) of over 10 percentage points to below 50%, regardless of symptoms. This definition encompasses both symptomatic and asymptomatic cases, as well as diastolic dysfunction. With increasing cancer survivorship, CTRCD has become a critical concern, particularly given the potential for delayed cardiac toxicity.
April, 2025 | Grand Rounds in Hematology & Oncology, Webinars
Dr. Gentzler delivers an informative and comprehensive update on the Experimental Therapeutics Clinical Trials Network (ETCTN), emphasizing its central role in the early-phase drug development pipeline supported by the National Cancer Institute (NCI).
April, 2025 | Grand Rounds in Hematology & Oncology, Lymphedema, Webinars
Dr. Mixon begins by defining lymphedema as a chronic, progressive condition often resulting from cancer treatment. A key focus is on identifying patients at high risk, including those undergoing lymph node dissection or radiation. She underscores the importance of risk stratification and proactive intervention to prevent progression to irreversible stages.
